Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 11 015 M
EBIT 2016 3 192 M
Net income 2016 1 054 M
Debt 2016 10 792 M
Yield 2016 -
Sales 2017 12 736 M
EBIT 2017 3 802 M
Net income 2017 2 119 M
Debt 2017 10 385 M
Yield 2017 -
P/E ratio 2016 27,06
P/E ratio 2017 13,37
EV / Sales2016 2,78x
EV / Sales2017 2,37x
Capitalization 19 836 M
More Financials
Company
Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products.It operates through two segments: Generic and Specialty.The Generic pharmaceutical business is conducted primarily in the U.S. and... 
Sector
Pharmaceuticals
Calendar
03/02Earnings Release
More about the company
Surperformance© ratings of Mylan Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on MYLAN INC
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/12DJCigna Drops Coverage of Mylan's EpiPen for Cheaper Generic -- Update
01/12DJCIGNA : Drops Coverage of Mylan's EpiPen for Cheaper Generic
01/11 MYLAN : U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Bioco..
01/09 MYLAN : to Present at the 35th Annual J.P. Morgan Healthcare Conference
01/09 MYLAN : Acquires Cold-EEZE® Brand to Further Expand OTC Business
2016 MYLAN : Launches Generic Concerta® Tablets
2016 MYLAN : Launches Generic Cerebyx® Injection
2016 MYLAN : Launches Generic Zovia® Tablets
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript
2015 Mylan Q4 revenues up 15%, Specialty up 38%
2015 Mylan (MYL) Q4 2014 Results - Earnings Call Webcast
2015 Mylan EPS in-line, beats on revenue
2015 Notable earnings after Monday?s close
Advertisement
Chart MYLAN INC
Duration : Period :
Mylan Inc Technical Analysis Chart | US6285301072 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 49,8 $
Spread / Average Target 34%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Heather M. Bresch Chief Executive Officer & Executive Director
Rajiv Malik President & Executive Director
Robert J. Coury Executive Chairman
Kenneth Scott Parks Chief Financial Officer
Wendy Cameron Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MYLAN INC-1.66%19 836
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
MERCK & CO., INC.6.22%172 404
More Results